Current Research and Use of Mesenchymal Stem Cells in the Therapy of Autoimmune Diseases

Author(s): Youdong Chen, Qian Yu, Yifan Hu, Yuling Shi*.

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 7 , 2019

Become EABM
Become Reviewer

Abstract:

Mesenchymal Stem Cells (MSCs) represent a heterogeneous group of self-renewal, multipotent non-hematopoietic stem cells, which display profound immunomodulatory functions and promising therapeutic effects. Autoimmune diseases, which result from an aberrant immune response to selfantigens, can be detrimental to nearly all body tissues. With the advance in developing a novel treatment, including biological agents, it is still impossible to cure autoimmune disorders. Recent studies demonstrate the remarkable therapeutic effectiveness of MSCs towards a wide array of autoimmune diseases. In this review, the immunomodulatory influence of MSCs over immune cells and the application of MSCs transplantation in treating autoimmune diseases are highlighted.

Keywords: Mesenchymal stem cell, autoimmune diseases, cellular therapy, psoriasis, RA, SLE, IBD, umbilical cord-derived MSC.

[1]
Adamo A, Dal Collo G, Bazzoni R, Krampera M. Role of mesenchymal stromal cell-derived extracellular vesicles in tumour microenvironment. Biochim Biophys Acta Rev Cancer 2018; 1871(1): 192-8.
[2]
Ribeiro A, Laranjeira P, Mendes S, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther 2013; 4(5): 125.
[3]
Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3(4): 393-403.
[4]
Casado JG, Tarazona R, Sanchez-Margallo FM NK. and MSCs crosstalk: The sense of immunomodulation and their sensitivity. Stem Cell Rev 2013; 9(2): 184-9.
[5]
Armiento AR, Alini M, Stoddart MJ. Articular fibrocartilage - Why does hyaline cartilage fail to repair? Adv Drug Deliv Rev 2018. S0169-409X(18)30319-3.
[6]
Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3(3): 301-13.
[7]
da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119(Pt 11): 2204-13.
[8]
Selleri S, Bifsha P, Civini S, et al. Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. Oncotarget 2016; 7(21): 30193-210.
[9]
Vasandan AB, Jahnavi S, Shashank C, Prasad P, Kumar A, Prasanna SJ. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism. Sci Rep 2016; 6: 38308.
[10]
Sala E, Genua M, Petti L, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Gastroenterology 2015; 149(1): 163-76.e20.
[11]
Cosenza S, Toupet K, Maumus M, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics 2018; 8(5): 1399-410.
[12]
Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ 2014; 21(2): 216-25.
[13]
Kidder D. Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int 2014; 85(4): 981-2.
[14]
Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 2014; 16(2): R79.
[15]
Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62(8): 2467-75.
[16]
Wang L, Wang L, Cong X, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: Safety and efficacy. Stem Cells Dev 2013; 22(24): 3192-202.
[17]
Panes J, Rimola J. Perianal fistulizing Crohn’s disease: Pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017; 14(11): 652-64.
[18]
Li JF, Zhang DJ, Geng T, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant 2014; 23(Suppl. 1): S113-22.
[19]
Chen H, Niu JW, Ning HM, et al. Treatment of Psoriasis with Mesenchymal Stem Cells. Am J Med 2016; 129(3): e13-4.
[20]
Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2: 8.
[21]
Thiel A, Yavanian G, Nastke MD, et al. Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritis. Sci Rep 2015; 5: 17685.
[22]
Wang D, Feng X, Lu L, et al. A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol 2014; 66(8): 2234-45.
[23]
Shi D, Wang D, Li X, et al. Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol 2012; 31(5): 841-6.
[24]
Li X, Wang D, Liang J, Zhang H, Sun L. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant 2013; 48(4): 544-50.
[25]
Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis 2017; 76(8): 1436-9.
[26]
Lee HK, Lim SH, Chung IS, et al. Preclinical efficacy and mechanisms of mesenchymal stem cells in animal models of autoimmune diseases. Immune Netw 2014; 14(2): 81-8.
[27]
Choi EW, Shin IS, Song JW, et al. Effects of transplantation of CTLA4Ig-overexpressing adipose tissue-derived mesenchymal stem cells in mice with sustained severe rheumatoid arthritis. Cell Transplant 2016; 25(2): 243-59.
[28]
Alvaro-Gracia JM, Jover JA, Garcia-Vicuna R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis 2017; 76(1): 196-202.
[29]
Arturo J, Perez C, Larios L, et al. Immunomodulation and induction of remission in crohn’s disease with autologous expanded mesenchymal stem cells. Case report. Cytotherapy 2014; 16(Suppl. 4): S101.
[30]
Kim HS, Shin TH, Lee BC, et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology 2013; 145(6): 1392-403.e8.
[31]
Fuenzalida P, Kurte M, Fernandez-O’ryan C, et al. Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium-induced colitis model. Cytotherapy 2016; 18(5): 630-41.
[32]
Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with crohn’s disease. Gastroenterology 2017; 153(1): 59-62.e2.
[33]
Yang H, Sun J, Wang F, Li Y, Bi J, Qu T. Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture - a preliminary study. Oncotarget 2016; 7(45): 72537-45.
[34]
Cohen JA, Imrey PB, Planchon SM, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler 2018; 24(4): 501-11.
[35]
Llufriu S, Sepulveda M, Blanco Y, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One 2014; 9(12)e113936
[36]
Campanati A, Orciani M, Sorgentoni G, et al. Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypical profile of psoriatic mesenchymal stem cells. Clin Exp Immunol 2018; 193(2): 234-40.
[37]
Sah SK, Park KH, Yun CO, Kang KS, Kim TY. Effects of human mesenchymal stem cells transduced with superoxide dismutase on imiquimod-induced psoriasis-like skin inflammation in mice. Antioxid Redox Signal 2016; 24(5): 233-48.
[38]
Comella K, Parlo M, Daly R, Dominessy K. First-in-man intravenous implantation of stromal vascular fraction in psoriasis: A case study. Int Med Case Rep J 2018; 11: 59-64.
[39]
De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: A case report. Cell Transplant 2016; 25(11): 2063-9.
[40]
Woods AC, Mant MJ. Amelioration of severe psoriasis with psoriatic arthritis for 20 years after allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis 2006; 65(5): 697.
[41]
Maria AT, Toupet K, Bony C, et al. Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis. Arthritis Rheumatol 2016; 68(4): 1013-25.
[42]
Christopeit M, Schendel M, Foll J, Muller LP, Keysser G, Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008; 22(5): 1062-4.
[43]
Liu M, Zeng X, Wang J, et al. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Stem Cell Res Ther 2016; 7(1): 63.
[44]
Reddy M, Fonseca L, Gowda S, Chougule B, Hari A, Totey S. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone. Int J Stem Cells 2016; 9(2): 192-206.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 7
Year: 2019
Page: [579 - 582]
Pages: 4
DOI: 10.2174/1574888X14666190429141421
Price: $65

Article Metrics

PDF: 28
HTML: 11